Key Points
- Director Robert Bessler sold 5,101 shares on April 21 at an average price of $7.01 for $35,758.01, leaving him with 1,309,397 shares (a 0.39% reduction in his position).
- Company outlook and actions: LifeStance missed EPS estimates for the quarter ($0.03 vs. $0.05) but grew revenue 17.4% year-over-year, its Board approved a $100 million buyback (up to 3.6% of shares), and analysts maintain a consensus "Moderate Buy" with a $9.83 price target.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Robert Bessler sold 5,101 shares of the business's stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $7.01, for a total value of $35,758.01. Following the completion of the sale, the director owned 1,309,397 shares of the company's stock, valued at $9,178,872.97. The trade was a 0.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
LifeStance Health Group Stock Up 1.2%
Shares of NASDAQ:LFST opened at $6.99 on Friday. The business's 50 day moving average is $6.73 and its 200 day moving average is $6.54. The stock has a market cap of $2.72 billion, a P/E ratio of 349.67 and a beta of 1.13. LifeStance Health Group, Inc. has a 52-week low of $3.74 and a 52-week high of $8.09. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.17.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The firm had revenue of $382.20 million for the quarter, compared to the consensus estimate of $378.51 million. During the same period last year, the firm earned ($0.01) earnings per share. The company's revenue for the quarter was up 17.4% on a year-over-year basis. Sell-side analysts predict that LifeStance Health Group, Inc. will post 0.09 EPS for the current year.
LifeStance Health Group declared that its Board of Directors has approved a stock repurchase plan on Wednesday, February 25th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 3.6% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its stock is undervalued.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Silversmith Partners I GP LLC purchased a new stake in LifeStance Health Group during the fourth quarter valued at approximately $100,842,000. AustralianSuper Pty Ltd purchased a new position in LifeStance Health Group in the third quarter worth $17,056,000. Vanguard Group Inc. increased its position in shares of LifeStance Health Group by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company's stock worth $124,608,000 after purchasing an additional 3,086,506 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of LifeStance Health Group by 62.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company's stock worth $26,363,000 after purchasing an additional 1,839,465 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company's stock valued at $45,998,000 after purchasing an additional 1,790,694 shares during the last quarter. Institutional investors own 85.50% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on LFST shares. KeyCorp upped their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Barclays boosted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an "overweight" rating in a report on Friday, March 6th. Canaccord Genuity Group upped their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Jefferies Financial Group upgraded shares of LifeStance Health Group to a "strong-buy" rating in a research note on Thursday, March 12th. Finally, Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a report on Sunday, February 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, LifeStance Health Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.83.
Get Our Latest Report on LFST
About LifeStance Health Group
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
